首页> 外文OA文献 >Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

【2h】

Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

机译：Tiantrakizumab（MK-3222）的药代动力学，抗IL-23单克隆抗体，在健康受试者中静脉内或皮下施用后

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Sauzanne Khalilieh; Peter Hodsman; Christine Xu; Anjela Tzontcheva; Shirley Glasgow; Diana Montgomery;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects [J] . Khalilieh Sauzanne, Hodsman Peter, Xu Christine, Basic & clinical pharmacology & toxicology. . 2018,第3期

机译：Tiantrakizumab（MK-3222）的药代动力学，抗IL-23单克隆抗体，在健康受试者中静脉内或皮下施用后
2. Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects [J] . Khalilieh Sauzanne, Hodsman Peter, Xu Christine, Basic & clinical pharmacology & toxicology. . 2018,第Suppla1期

机译：Tiantrakizumab（MK-3222）的药代动力学，抗IL-23单克隆抗体，在健康受试者中静脉内或皮下施用后
3. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, followingsingle-dose administration by subcutaneous and intravenous routes in healthy subjects [J] . ZhangX., GeorgyA., RowellL. International journal of clinical pharmacology and therapeutics . 2013,第6期

机译：ToColizumab的药代动力学和药效学，一种人源化的抗白细胞介素-6受体单克隆抗体，通过皮下和静脉注射治疗的静脉剂量给药
4. Comparative Pharmacokinetics and Bioavailability of Ceftiofur in Horses After Intravenous, Intramuscular, and Subcutaneous Administration [C] . Nathan M. Slovis, W. David Wilson, Scott Stanley, Annual Convention of the American Association of Equine Practitioners . 2006

机译：静脉内，肌肉内，皮下给药后马匹托呋喃的比较药代动力学和生物利用度
5. Challenges Facing the Subcutaneous Administration of Therapeutic Monoclonal Antibodies [D] . Turner, Michael R. 2019

机译：皮下给药治疗性单克隆抗体面临的挑战
6. A Randomized Study of the Relative Pharmacokinetics Pharmacodynamics and Safety of Alirocumab a Fully Human Monoclonal Antibody to PCSK9 After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects [O] . Catherine Lunven, Tobias Paehler, Franck Poitiers, -1

机译：在健康受试者的三个不同注射部位进行单次皮下给药后对PCSK9的全人类单克隆抗体Alirocumab的相对药代动力学药效学和安全性的随机研究
7. FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE) [O] . C. Barbey, H. Naik, C. Musselli, 2018

机译：Fri0315 BiiB059的安全性，耐受性，药代动力学和药效学和药效动性效应，静脉注射（IV）和皮下（SC）单或多剂量给药在健康卷（HV）和有活性系统狼疮（SLE）中的受试者（SLE）

Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

著录项

引文网络

相似文献

相关主题

期刊订阅